{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+%28Period+1%29", "query": { "intervention": "Placebo injection (Period 1)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 302, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+%28Period+1%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T02:33:32.615Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04888585", "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "ABBV-154", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 473, "start_date": "2021-06-23", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 101, "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04888585" }, { "nct_id": "NCT05103332", "title": "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Indapamide", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Olmesartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Zilebesiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 663, "start_date": "2021-11-05", "completion_date": "2024-09-13", "has_results": true, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 74, "location_summary": "Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103332" }, { "nct_id": "NCT03587701", "title": "Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Inner Ear Disease", "Meniere's Disease" ], "interventions": [ { "name": "Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)", "type": "DRUG" }, { "name": "Placebo injection (Period 1)", "type": "DRUG" }, { "name": "Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)", "type": "DRUG" }, { "name": "Placebo injection (Period 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2019-01-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587701" }, { "nct_id": "NCT04033926", "title": "A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polymyositis", "Dermatomyositis" ], "interventions": [ { "name": "KZR-616", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-01-14", "completion_date": "2022-04-06", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 12, "location_summary": "Beverly Hills, California • Orange, California • Miami, Florida + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033926" }, { "nct_id": "NCT07229911", "title": "A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Primary Sclerosing Cholangitis" ], "interventions": [ { "name": "TAK-781", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "68 Years", "sex": "ALL", "summary": "18 Years to 68 Years" }, "enrollment_count": 134, "start_date": "2026-01-07", "completion_date": "2028-04-06", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07229911" }, { "nct_id": "NCT04200092", "title": "Staccato® Granisetron Single Dose PK", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "0.5mg AZ-010; placebo", "type": "COMBINATION_PRODUCT" }, { "name": "1mg AZ-010", "type": "COMBINATION_PRODUCT" }, { "name": "3mg AZ-010", "type": "COMBINATION_PRODUCT" }, { "name": "AZ-010 1mg", "type": "COMBINATION_PRODUCT" }, { "name": "IV Granisetron 1mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "OTHER" ], "sponsor": "Nova Pneuma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 36, "start_date": "2019-11-04", "completion_date": "2020-01-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200092" }, { "nct_id": "NCT00264550", "title": "An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Golimumab 100 mg", "type": "DRUG" }, { "name": "Golimumab 50 mg", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2005-12", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 13, "location_summary": "Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00264550" }, { "nct_id": "NCT06780449", "title": "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo cagrilintide", "type": "DRUG" }, { "name": "Placebo semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-02-10", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 10, "location_summary": "Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Covina", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780449" }, { "nct_id": "NCT02076178", "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "744 Tablet", "type": "DRUG" }, { "name": "744 LA Injection", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "DRUG" }, { "name": "Placebo Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 127, "start_date": "2014-03-27", "completion_date": "2016-02-23", "has_results": true, "last_update_posted_date": "2017-12-15", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02076178" }, { "nct_id": "NCT02483078", "title": "Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "PRO 140", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Optimized Background Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2015-10", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2022-11-03", "last_synced_at": "2026-09-29T02:33:32.615Z", "location_count": 34, "location_summary": "Fountain Valley, California • Long Beach, California • Los Angeles, California + 24 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02483078" } ] }